Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.03
-0.17 (-1.05%)
At close: Oct 30, 2026, 4:00 PM EDT
15.98
-0.05 (-0.32%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $30.25. The average 1-year stock price forecast is 88.71% higher than the current stock price, while the lowest is $11.92 (-25.64%) and the highest is $43.8 (+173.24%).
Price Target: $30.25 (+88.71%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 7 | 6 | 6 |
| Sell | 2 | 2 | 2 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Oct 28, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $41 → $43 | Buy | Maintains | $41 → $43 | +168.25% | Oct 26, 2026 |
| Bernstein | Bernstein | Hold Maintains $12 | Hold | Maintains | $12 | -25.76% | Oct 26, 2026 |
| UBS | UBS | Buy Maintains $33 | Buy | Maintains | $33 | +105.86% | Oct 26, 2026 |
| Citi | Citi | Buy Maintains $43 | Buy | Maintains | $43 | +168.25% | Oct 26, 2026 |
Financial Forecast
Revenue This Year
3.93M
Revenue Next Year
56.17M
from 3.93M
Increased by 1,328.24%
EPS This Year
-1.12
from -1.43
EPS Next Year
-1.17
from -1.12
EPS and Forward PE are based on non-GAAP adjusted numbers.